FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家银行表示，尽管受到一次性波动的影响，百时美施贵宝第一季度业绩仍有望达到预期。

-- 加拿大皇家银行资本市场（RBC Capital Markets）周五在一份报告中表示，百时美施贵宝（Bristol-Myers Squibb，股票代码：BMY）第一季度业绩预计将与市场预期一致，但肿瘤业务销售疲软以及一些一次性因素可能会导致业绩波动。 该投资公司表示，由于去库存模式带来的波动、同比基数较高、政策影响以及仿制药上市阶段等因素，本季度业绩难以预测。 加拿大皇家银行预计，百时美施贵宝第一季度营收将达到107.5亿美元，每股收益为1.42美元。FactSet调查的分析师预计，百时美施贵宝非GAAP每股收益为1.42美元，GAAP每股收益为1.17美元，营收为108.7亿美元。 投资者在季度财报电话会议上的关注点将集中在公司即将公布的临床试验结果上，特别是候选药物milvexian和cobenfy的后期临床试验数据，这些数据对于判断百时美施贵宝何时恢复增长至关重要。 百时美施贵宝将于4月30日公布第一季度财报。 加拿大皇家银行（RBC）对该股的评级为“与行业持平”，目标价为60美元。

Price: $58.62, Change: $-0.85, Percent Change: -1.44%

Related Articles

Equities

Petro Rabigh Emerges From Loss in Q1; Revenue Grows

Rabigh Refining and Petrochemical (SASE:2380), d/b/a Petro Rabigh, said Sunday it swung back to profit in the first quarter of 2026, while revenue increased year over year.Net profit attributable to shareholders of the issuer for the three months ended March 31 was 1.47 billion Saudi riyals, compared with the attributable loss of 691 million riyals earlier. EPS moved to 0.88 riyal from a loss per share of 0.41 riyal.The Tadawul-listed oil refining and petrochemical company's revenue was 14.85 billion riyals, compared with 11.21 billion riyals a year ago.

$SASE:2380
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR